PeptiDream

Curium partners with PDRadiopharma to advance clinical development, regulatory filing, and commercialization of PSMA-targeting theranostics 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan. 177Lu-PSMA-I&T is in phase 3 ECLIPSE trial for metastatic castration-resistant prostate cancer, while 64Cu-PSMA-I&T is in phase 3 SOLAR RECUR and SOLAR STAGE trials for prostate cancer diagnostics.

The global peptide therapeutics market is projected to grow from $42.1B in 2023 to $56.2B by 2030, driven by technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. Peptide therapeutics offer high specificity and low toxicity, making them attractive for treating conditions like cancer and diabetes. Innovations in peptide engineering and delivery systems are enhancing their efficacy and stability, expanding their therapeutic potential across various diseases.

Big Pharmas are aggressively acquiring radiopharmaceutical biotechs, inspired by Novartis' success with therapies like Pluvicto and Lutathera. Companies like Eli Lilly, Bristol Myers Squibb, and Sanofi are making significant investments, with deals involving Aktis Oncology, ARTBIO, Nucleus RadioPharma, PeptiDream, and RadioMedix, highlighting the sector's growth and potential.

Novartis invests over $200 million in a new 10,000 sq ft radiotherapy facility in Carlsbad, creating 30+ jobs. The facility focuses on radioligand therapy manufacturing, aiming to improve cancer treatment precision. This marks Novartis' first U.S. manufacturing facility in California.

Orbis Medicines, backed by €26M, aims to develop orally dosed peptide-based drugs using macrocycles for better bioavailability and cellular permeability. Their technology enables rapid synthesis and screening of compounds, targeting validated antibody drug targets for more convenient patient treatment.

The global peptide cancer therapeutics market is projected to exceed US$ 20 billion by 2026, driven by the increasing prevalence of cancer and the demand for efficient treatments. Over 150 cancer peptides are in clinical trials, with more than 20 already marketed. Peptides offer advantages like high tissue permeability and the ability to cross the blood-brain barrier, making them effective in cancer management. Major pharmaceutical companies are investing in peptide-based drugs, with strategic alliances and new product launches fueling market growth.